Clinical trials for psychedelics include screening for disqualifying conditions such as psychotic disorders and cardiovascular issues. — Whalespan
Clinical trials for psychedelics include screening for disqualifying conditions such as psychotic disorders and cardiovascular issues.
⚠ High risk
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
✓WELLSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“So the main ones being the psychotic disorders, schizophrenia, and also including bipolar. - Right. - So the manic side of bipolar. - Mm-hmm. - So after that... And also cardiovascular screening, heart disease.”
Verbal pushback — no audited source on record.
88
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
“So people are screened out if they have any even second degree relative with history of psychotic disorder or bipolar disorder. So we're conservative in that regard, but we're concerned with that as a vulnerability.”